287 related articles for article (PubMed ID: 21660364)
1. Anticancer activity of tetracationic arene ruthenium metalla-cycles.
Barry NP; Edafe F; Therrien B
Dalton Trans; 2011 Jul; 40(27):7172-80. PubMed ID: 21660364
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity of opened arene ruthenium metalla-assemblies.
Barry NP; Zava O; Furrer J; Dyson PJ; Therrien B
Dalton Trans; 2010 Jun; 39(22):5272-7. PubMed ID: 20442944
[TBL] [Abstract][Full Text] [Related]
3. Anticancer potency studies of coordination driven self-assembled arene–Ru-based metalla-bowls.
Mishra A; Jeong YJ; Jo JH; Kang SC; Lah MS; Chi KW
Chembiochem; 2014 Mar; 15(5):695-700. PubMed ID: 24677392
[TBL] [Abstract][Full Text] [Related]
4. Anticancer activity of osmium metalla-rectangles.
Barry NP; Edafe F; Dyson PJ; Therrien B
Dalton Trans; 2010 Mar; 39(11):2816-20. PubMed ID: 20200707
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterisation and in vitro anticancer activity of hexanuclear thiolato-bridged arene ruthenium metalla-prisms.
Furrer MA; Garci A; Denoyelle-Di-Muro E; Trouillas P; Giannini F; Furrer J; Clavel CM; Dyson PJ; Süss-Fink G; Therrien B
Chemistry; 2013 Feb; 19(9):3198-203. PubMed ID: 23344898
[TBL] [Abstract][Full Text] [Related]
6. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
7. Thiophenolato-bridged dinuclear arene ruthenium complexes: a new family of highly cytotoxic anticancer agents.
Gras M; Therrien B; Süss-Fink G; Zava O; Dyson PJ
Dalton Trans; 2010 Nov; 39(42):10305-13. PubMed ID: 20890536
[TBL] [Abstract][Full Text] [Related]
8. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
9. Ruthenium(II) arene anticancer complexes with redox-active diamine ligands.
Bugarcic T; Habtemariam A; Deeth RJ; Fabbiani FP; Parsons S; Sadler PJ
Inorg Chem; 2009 Oct; 48(19):9444-53. PubMed ID: 19780621
[TBL] [Abstract][Full Text] [Related]
10. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
[TBL] [Abstract][Full Text] [Related]
11. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
12. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
13. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
[TBL] [Abstract][Full Text] [Related]
14. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
15. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
16. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Anticancer Activity, and Genome Profiling of Thiazolo Arene Ruthenium Complexes.
Grozav A; Balacescu O; Balacescu L; Cheminel T; Berindan-Neagoe I; Therrien B
J Med Chem; 2015 Nov; 58(21):8475-90. PubMed ID: 26488797
[TBL] [Abstract][Full Text] [Related]
18. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
19. Use of perfluorinated phosphines to provide thermomorphic anticancer complexes for heat-based tumor targeting.
Renfrew AK; Scopelliti R; Dyson PJ
Inorg Chem; 2010 Mar; 49(5):2239-46. PubMed ID: 20131860
[TBL] [Abstract][Full Text] [Related]
20. Heteroleptic arene ruthenium complexes based on meso-substituted dipyrrins: synthesis, structure, reactivity, and electrochemical studies.
Yadav M; Singh AK; Maiti B; Pandey DS
Inorg Chem; 2009 Aug; 48(16):7593-603. PubMed ID: 19610658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
